Table 2.
Univariate comparison of patients with hemorrhagic versus nonhemorrhagic transformation.
| Hemorrhagic transformation (n = 32) | Nonhemorrhagic transformation (n = 59) | p | |
|---|---|---|---|
| Characteristic | |||
| Age on admission (y), median (range) | 70 (53-91) | 71 (60-87) | 0.357 |
| Women, n (%) | 14 (43.8%) | 30 (50.8%) | 0.514 |
| NIHSS on admission, median (range) | 14 (6-23) | 15 (3-22) | 0.558 |
| Interventional parameters | |||
| TICI (2b-3 score), n (%) | 27 (84.4%) | 57 (96.6%) | 0.092 |
| Bridging therapy, n (%) | 20 (62.5%) | 32 (54.2%) | 0.656 |
| TOAST, n (%) | 0.538 | ||
| Atherosclerotic | 12 (37.5%) | 18 (30.5%) | |
| Cardioembolic | 18 (56.3%) | 38 (64.4%) | |
| Other | 1 (6.2%) | 3 (5.1%) | |
| Vascular risk factors, n (%) | |||
| Hypertension | 18 (56.3%) | 45 (76.3%) | 0.059 |
| Diabetes mellitus | 4 (12.5%) | 14 (23.7%) | 0.272 |
| Coronary heart disease | 6 (18.8%) | 12 (20.3%) | 0.557 |
| Clinical outcome, n (%) | 0.514 | ||
| mRS (0-2) | 17 (53.1%) | 35 (59.3%) | |
| mRS (3–6) | 15 (46.9%) | 24 (40.7%) | |
| Mortality | 8 (25%) | 7 (11.9%) | 0.141 |
| Thrombus components, median (SD) | |||
| CD4+ cells∗ | 2 (1.7) | 13 (5.6) | <0.001 |
| CD25+ cells∗ | 3 (1.5) | 11 (7.2) | <0.001 |
NIHSS: National Institutes of Health Stroke Scale; TICI: thrombolysis in cerebral infarction; TOAST: Trial of Org 10172 in Acute Stroke Treatment; mRS: modified Rankin Scale. ∗Primary target variables.